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The main metabolic pathway of ethanol metabolism is the bioactivation to acetaldehyde catalyzed by cytosolic alcohol dehydrogenase and the detoxifi-
cation to acetate catalyzed by mitochondrial aldehyde dehydrogenase. 
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Abstract: Background: It is well known that ethanol can cause significant morbidity and mortality, and much of 
the related toxic effects can be explained by its metabolic profile. 
Objective: This work performs a complete review of the metabolism of ethanol focusing on both major and minor 
metabolites. 
Method: An exhaustive literature search was carried out using textual and structural queries for ethanol and related 
known metabolizing enzymes and metabolites. 
Results: The main pathway of metabolism is catalyzed by cytosolic alcohol dehydrogenase, which exhibits multiple isoenzymes and ge-
netic polymorphisms with clinical and forensic implications. Another two oxidative routes, the highly inducible CYP2E1 system and 
peroxisomal catalase may acquire relevance under specific circumstances. In addition to oxidative metabolism, ethanol also originates 
minor metabolites such as ethyl glucuronide, ethyl sulfate, ethyl phosphate, ethyl nitrite, phosphatidylethanol and fatty acid ethyl esters. 
These metabolites represent alternative biomarkers since they can be detected several hours or days after ethanol exposure. 
Conclusion: It is expected that knowing the metabolomics of ethanol may provide additional insights to better understand the toxicologi-
cal effects and the variability of dose response. 
Keywords: Ethanol, metabolomics, oxidative, non-oxidative, major metabolites, minor metabolites, biomarkers. 
INTRODUCTION 
 Ethanol abuse is associated with significant morbidity and mor-
tality [1, 2]. Blood ethanol concentrations are the result of upper 
gastrointestinal absorption by passive diffusion, uniform distribu-
tion in body water, metabolism and unchanged excretion [3]. Etha-
nol absorption is a fast process since it is a small molecule highly 
soluble in water, but not in fat [4]. Twenty percent of ethanol is 
absorbed in the stomach and 80% in the upper small intestine. In 
the gastric mucosa (and not in the small intestine), 5-10% of etha-
nol is metabolized by alcohol dehydrogenase isoform (or isozyme) 
7 (ADH7) and this is called gastric first pass metabolism of ethanol 
[3, 4]. The remaining ethanol accesses the liver via the portal vein 
where it is partially metabolized, since some flows out of the liver 
without being metabolized. Peak blood ethanol concentrations usu-
ally occur within 30-90 minutes of ingestion. Ninety percent of 
ethanol is metabolized in the liver after multiple passages but the 
lungs (especially via CYP2E1) also contribute to metabolism. Un-
changed ethanol is eliminated in small quantities (approximately 
5% of orally absorbed ethanol) by the kidneys (0.5–2%), lungs 
(1.6–6%) and skin (<0.5%) [4]. 
 Fifty years ago, it was believed that the metabolism of ethanol 
involving multiple forms of ADH was the only significant pathway 
[1]. Indeed, ethanol is primarily bioactivated (92-95%) by cytosolic 
(especially hepatic) ADH1B into acetaldehyde, which has proved to 
have mutagen and carcinogen effects [1]. At high blood ethanol 
levels, the microsomal ethanol-oxidizing system (CYP2E1 isoform, 
located in the smooth endoplasmic reticulum) also has an important 
role. Ethanol itself induces the activity of CYP2E1, and therefore 
also influences the metabolism of other xenobiotics (e.g., paraceta-
mol and cocaine). Through CYP2E1, reactive oxygen species 
(ROS) are produced and lipid peroxidation may occur. Catalase is 
of minor importance (responsible for approximately 5%) in the 
metabolism of ethanol. Acetaldehyde is subsequently detoxified to 
acetate, mainly by the mitochondrial enzyme aldehyde  
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dehydrogenase (ALDH2) [5]. In addition to oxidative metabolism, 
ethanol also originates minor metabolites such as ethyl glucuronide 
(EtG), ethyl sulfate (EtS), ethyl nitrite (EtN), ethyl phosphate (EtP) 
phosphatidylethanol (PEth) and fatty acid ethyl esters (FAEE; e.g., 
ethyl palmitate, ethyl oleate, and ethyl stearate), which can be de-
tected several hours or days after ethanol exposure, representing 
alternative biomarkers of exposure [6, 7]. This non-oxidative me-
tabolism is less useful in explaining toxic effects of ethanol, but is 
highly important for monitoring consumption due to longer half-
lives. Indeed, ethanol has a short half-life, which means that it pos-
sess a reduced value as an exposure biomarker. 
 This work reviews all known oxidative and non-oxidative 
metabolic routes of ethanol, focusing on both major and minor me-
tabolites with forensic and clinical toxicology. 
ALCOHOL DEHYDROGENASE 
 Ethanol metabolism involves primarily multiple isoforms of 
cytosolic ADHs and it is the rate-limiting step. These belong to the 
medium chain dehydrogenases/reductases (MDRs), which typically 
catalyze oxidation of simple alcohols (such as methanol and etha-
nol) to aldehydes (namely, formaldehyde and acetaldehyde), cou-
pled with the reduction of NAD
+
 to NADH (Fig. 1) [1]. Besides 
xenobiotics, ADHs also metabolize endobiotics such as dehydroge-
nation of hydroxysteroids, oxidation of intermediary alcohols and 
m-oxidation of fatty acids [8]. There are seven human ADHs, and 
these are divided into five classes (I-V) based on patterns of tissue-
specific expression, catalytic properties, and amino acid sequence 
(Table 1) [9, 10]: 
a) Class I – comprises ADH1A or -ADH, ADH1B or -ADH, 
and ADH1C or -ADH (formerly known as ADH1, ADH2, 
and ADH3, respectively) with homodimeric and heterodimeric 
forms of the 3 subunits (e.g., , , , , , etc.); 
b) Class II – comprises ADH4 with 2 pi subunits (); 
c) Class III - comprises ADH5 with 2 chi subunits (); 
d) Class IV - comprises ADH7 with 2 sigma subunits (); 
e) Class V - comprises ADH6 (for which there is no subunit des-
ignation). 
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 The need to clear the body of small amounts of ethanol pro-
duced by fermentation in the gut may explain its utility [11]. Etha-
nol is not capable of inducing its own metabolism via ADH. 
 Class I ADH isozymes are responsible for the oxidation of 
ethanol and other small aliphatic alcohols, and are strongly inhib-
ited by pyrazole and its 4-alkyl derivatives (e.g., 4-methylpyrazole 
or fomepizole). They exhibit high affinity (low Km; reacting at a 
relatively low concentration) but low capacity (high Vmax) for etha-
nol. High levels of class I ADH isozymes are present in the liver 
(especially in the centrolobular area) and adrenals, with lower lev-
els in the kidneys, lungs, blood vessels (in the case of ADH1B), 
gastric mucosa (in the case of ADH1C), and other tissues, but not in 
the brain or placenta. It is worth noting that the liver expresses a 
very large amount of ADHs (approximately 3% of all soluble pro-
tein) and also the widest variety of isozymes [9]. 
 Genetic polymorphisms have been well described for class I 
ADH isozymes, resulting in different affinities (Km) and/or capacity 
(Vmax) for oxidizing ethanol to acetaldehyde. There are at least 3 
allelic variants of ADH1B (i.e., *1, *2, and *3), with a single amino 
acid change at position 48. The homodimer, 22, and heterodimers 
of at least one 2 subunit (i.e., ADH1B*2) are particularly active in 
the oxidation of ethanol. Indeed, ADH1B*2 (formerly known as 
ADH2*2) is known as “atypical” ADH, and is responsible for the 
unusually rapid metabolism (40 times more active than the enzyme 
encoded by the ADH1B1 allele) of ethanol to acetaldehyde in up to 
90% of the East Asian population, whereas only 10% of Cauca-
sians express this allele. ADH1B*3 is relatively common in indi-
viduals of African descent. The latter two alleles have greater activ-
ity toward ethanol than the ADH1B1*1 allele [12]. These popula-
tion differences in ADH1B allelozyme expression contribute to 
ethnic differences in ethanol consumption and toxicity. Indeed, 
since individuals with the ADH1B2 allele produce relevant 
amounts of acetaldehyde and experience its toxic effects (e.g., 
flushing, tachycardia, diaphoresis, nausea and vomiting), they tend 
to avoid ethanol consumption. Unlike the allelic variants of 
ADH1B, the allelic variants of ADH1C do not differ markedly in 
their ability to oxidize ethanol. Nevertheless, it has been demon-
strated that the ADH1C1 allele encodes for an enzyme that is 2.5 
times more active in producing acetaldehyde than ADH1C2 [13].  
 The class II enzyme ADH4 (-ADH) is mainly expressed in the 
liver (and to some extent in other gastrointestinal tissues), where it 
preferentially oxidizes larger alcohols but may play some role in 
ethanol oxidation, especially at high concentrations [12]. Indeed, 
ADH4 has a relatively high Km and negligible the fomepzole inhibi-
tion. Some studies support a role for polymorphisms of ADH4 in 
susceptibility to alcoholism [12]. 
 The class IV enzyme ADH7 (-ADH; also referred to as the μ 
subunit) is a low-affinity but high-capacity enzyme for oxidizing 
ethanol. Indeed, among the human ADH forms, ADH7 has the 
highest activity toward ethanol [14]. It is the main ADH expressed 
in human gastric mucosa (also ADH1C and ADH3) and other cells 
in the upper gastrointestinal tract (e.g., esophagus, pharynx, gin-
giva, mouth, and tongue), and in the cornea [14]. This localization 
is of considerable interest in the gastric first pass metabolism of 
 
Fig. (1). Oxidative and non-oxidative metabolism of ethanol. Approximately 5% of ethanol is excreted unchanged in urine (0.5-2.0%), sweat (<0.5%) and 
breath (1.6-6.0%). In gray color are the enzymes that catalyze the respective reactions. 
 
Table 1. Principal characteristics of ADH isoforms [9, 118]. 
Are Zn metalloenzymes 
Cytosolic enzymes present in tissues such as the liver (which has the highest levels), kidneys, lungs, and gastric mucosa 
Are dimeric proteins consisting of two 40-kDa subunits , , , , ,  (formerly known as ), or ADH6 (there is no subunit term) 
7 AHD isoforms: Class I (ADH1A, ADH1B and ADH1C), Class II (ADH4), Class III (ADH5), Class V (ADH6), Class IV (ADH7) 
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ethanol since it may explain the development of cancer in the gas-
trointestinal tract due to acetaldehyde exposure [1, 4]. In contrast to 
the other ADHs, ADH7 is not expressed in the adult human liver 
[9]. Its contribution to ethanol metabolism is no more than 5-10% 
in vivo but may be significantly influenced by a number of factors 
[15] (Table 2). The role of a protective effect against alcoholism of 
high-activity ADH7 polymorphisms remains to be fully clarified, 
with some studies showing a positive association [14], and others 
no association [16, 17]. However, A92G SNP (rs1573496; C  G) 
in ADH7 has been found to result in a reduced risk of squamous 
cell carcinoma of the head and neck in Caucasians [18]. 
 Several experiments carried out with human volunteers have 
found that plasma levels of acetaldehyde are higher in alcoholics 
than non-alcoholics, probably due to the vicious cycle manifested 
by the toxic effects of acetaldehyde on mitochondrion [19].  
CYP2E1 
 A second pathway of ethanol metabolism, the microsomal etha-
nol oxidizing system (MEOS), was first described almost fifty years 
ago. CYP2E1 utilizes the reduced form of nicotinamide adenine 
dinucleotide phosphate (NADPH) as a cofactor, and also requires 
O2, which is reduced to water during catalysis. The Km of CYP2E1 
for ethanol is 10 mM, which is roughly one order of magnitude 
higher than that of ADH1. Therefore, at low blood ethanol levels, 
the contribution of CYP2E1 to its oxidation is limited, acquiring an 
important role only at high levels of ethanol consumption [20]. 
 Unlike the other two major pathways, a 4-10-fold increase of 
CYP2E1 expression has been associated with ethanol abuse [21, 
22]. This induction explains tolerance to the desirable/expected 
effects of ethanol after chronic consumption and cross-tolerance 
with other CYP2E1 substrates [23]. Indeed, in addition to CYP1A2 
and CYP3A4, CYP2E1 is also recognized as a key enzyme in-
volved in the bioactivation of paracetamol to its liver reactive me-
tabolite N-acetyl-p-benzoquinone imine (NAPQI) [24, 25]. 
CYP2E1 also metabolizes a large number of volatile halogenated 
alkanes (e.g., chloroform, carbon tetrachloride, vinyl chloride, and 
many more), halogenated anesthetics (e.g., halothane, enflurane, 
and others), small aromatic and nitrogen aromatic compounds (e.g., 
benzene, styrene, toluene, pyridine, pyrazole, and others), alkanes 
(ethane-hexane), other alcohols besides ethanol (e.g., primary ali-
phatic alcohols such as methanol and propanol, secondary alcohols 
such as isopropanol and tertiary alcohols such as t-butanol), co-
caine, the colon carcinogen azoxymethane, and numerous 
mutagenic/carcinogenic nitrosamines [26]. 
 CYP2E1 is expressed in the liver (i.e., the smooth endoplasmic 
reticulum of the centrolobular area) and several extrahepatic tissues, 
such as the kidneys, pancreas, brain, lungs, intestine, nasal epithe-
lium, bone marrow, and lymphocytes. Low levels of CYP2E1 are 
also expressed in the human fetal liver and prenatal brain, suggest-
ing ROS involvement in fetal alcohol syndrome [27]. Numerous 
genetic polymorphisms in the CYP2E1 gene have been identified 
but none gives rise to a poor- or ultra-metabolizer phenotype [26]. 
In rat liver, approximately 40% of CYP2E1 is phosphorylated and 
localized to the inner membrane of mitochondria [28]. 
 Compared with other isoforms of P450, CYP2E1 exhibits a 
higher rate of oxidase activity [29]. From this activity, ROS are 
produced even in the absence of substrate, similarly to CYP1A2 
(the other high-spin enzyme) [30-32]. During its catalytic cycle 
CYP2E1 is prone to uncoupling, so that, during the metabolism of 
ethanol, approximately 50% of the cycles result in the production of 
superoxide anion (O2
.-
) and related ROS instead of metabolite forma-
tion [33, 34]. Accordingly, several studies have demonstrated that 
antioxidants can protect against ethanol-related toxic effects [35]. 
 The CYP2E1-catalyzed metabolism of ethanol produces an 
unstable intermediate (i.e., a gem-diol) that decomposes to acetal-
dehyde. Moreover, since ROS are produced, CYP2E1 indirectly 
catalyzes the formation of a radical species from ethanol itself (i.e., 
1 (or )-hydroxyethyl radical - CH3HOH), which also contributes 
to oxidative damage [36]. The detection of the 1-hydroxyethyl radi-
cal has been suggested as a useful proof of oxidative stress in vivo 
as a consequence of ethanol exposure [37]. Although not yet com-
pletely understood, two mechanisms of hydroxyethyl radical forma-
tion have been proposed: 
a) NADPH-oxidase activity of CYP2E1 is responsible for the 
formation of O2
.-
and H2O2. The interaction of transition metals 
Table 2. Factors that may influence the gastric first pass metabolism of ethanol [15, 109, 119-122]. 
The manner of consumption: large doses over a short time (e.g., shots) produce high ethanol concentrations in the stomach, which compensate for the 
high Km of gastric ADH7 
Age and gender: young women have lower gastric ADH7 activity than men. ADH7 activity in men decreases and reaches the level in females at the age of 
65 or older 
Alcoholics: gastric ADH7 activity tends to be lower (some alcoholic women have no detectable gastric ADH7, and blood levels of ethanol after oral con-
sumption of alcohol are the same as those that are obtained after intravenous administration 
Fasting: decreases ADH7 activity (ethanol is more intoxicating when consumed on an empty stomach) 
Noncompetitive inhibitors: commonly used drugs [e.g., cimetidine (inhibits ADH7 activity), ranitidine (enhanced gastric emptying with a decreased con-
tact time of ethanol with gastric ADH7), tramadol, and aspirin (injure gastric mucosa leading to a decrease in gastric production] increase the systemic 
availability of ethanol, although the effect is too small to have serious medical, social, or legal consequences 
Ethnicity: 30% of Asians appear to be genetically deficient in ADH7 
Rate of gastric emptying: if delayed, increases gastric first pass metabolism and vice-versa. This may be of relevance when ethanol is taken together with 
food (fat delays gastric emptying) or in diabetic patients with gastroparesis 
Gastric morphology: atrophic gastritis or gastric atrophy decreases gastric parietal cell mass and therefore the amount of ADH in the stomach 
Helicobacter pylori: decreases first pass effect. Although this bacteria has ADH activity and produces acetaldehyde from ethanol (as other microorganisms 
may do) this effect is counteracted by the damaging effects of the bacteria on gastric mucosa 
Polymorphism of ADH1C 
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(e.g., Fe
2+
 and Cu
+
) with H2O2 produces HO
.
 that, by reacting 
(scavenging) with ethanol, may give rise to less reactive hy-
droxyethyl free radicals; 
b) Direct one-electron oxidation of ethanol by O2
.-
 at the catalytic 
site of the enzyme may also account for the formation of etha-
nol-derived radical species as a result of interaction of ethanol 
with the ferric cytochrome P450-oxygen complex (CYP2E1-
Fe
3+
O2
-
). 
 Interestingly, it has been shown that acetaldehyde may also be 
oxidized by CYP2E1 to acetate, a reaction that will be always neg-
ligible [38] if it occurs at all. 
 CYP2E1 can be inhibited by 4-methylpyrazole (fomepizole), 
which also inhibits ADH (class I ADH), and by disulfiram 
(Antabuse), which also inhibits ALDH (ADH2). Males exhibit 
higher activity of CYP2E1 and this isoenzyme is induced by fasting 
and prolonged starvation [39-41]. 
NITRIC OXIDE SYNTHASE 
 Nitric oxide synthase (NOS), a member of the same superfa-
mily of enzymes [42] that includes cytochrome P450, oxidizes l-
arginine to l-citrulline and nitric oxide (NO) [43]. This enzyme can 
also transfer electrons to O2 to form O2
.-
 and H2O2. Porasuphatana 
et al. [44] demonstrated that, in the presence of l-arginine, NOS1 
(neuronal) and NOS2 (inducible) can metabolize ethanol to a 1-
hydroxyethyl radical. Authors have also observed that once this free 
radical is formed, it is metabolized to acetaldehyde. 
CATALASE 
 It is also known that the peroxisomal catalase is capable of oxi-
dizing ethanol in the presence of H2O2 [45]. Nevertheless, under 
physiological conditions, catalase seems to play an insignificant 
role [46]. Indeed, it is estimated that <5% of an ethanol dose is 
metabolized through this pathway [4, 46]. In this reaction, ethanol 
functions as an electron donor for the reduction of H2O2 to water. 
Thus, the capacity of this pathway is limited due to the low levels 
of H2O2 and, like CYP2E1, is also associated with the generation of 
ROS. 
 Several polymorphisms in the catalase gene have been de-
scribed, but these do not alter enzymatic activity [47]. It has also 
been suggested that acetaldehyde produced in the brain (where 
ADH is inactive) due to metabolism of ethanol by catalase plays a 
role in the development of tolerance and in the positive reinforcing 
actions of ethanol [48]. 
ALDEHYDE DEHYDROGENASE 
 ALDHs (especially ALDH2 but also ALDH1B1 and ALDH1A) 
oxidize acetaldehyde to acetic acid [1, 49]. This pathway generally 
uses NAD
+
 as the cofactor that is reduced to NADH. ALDH en-
zymes are involved in the oxidation of other aldehydes, such as 
those formed from allyl alcohol, carbon tetrachloride, cyclophos-
phamide, and ifosfamide [46].  
 Besides ADH, relevant polymorphism with toxicological sig-
nificance involves the mitochondrial ALDH2, with the ALDH2*2 
isoform showing low or no catalytic activity (the wild type variant 
is ALDH2*1) [50]. ALDH2 is expressed at the highest levels in the 
liver, although it can also be found in other tissues such as kidney, 
skeletal, cardiac muscle, and mammary tissues. Since ALDH2*2 is 
found in 40%-50% of East Asians but is absent in Caucasians, this 
may explain the low incidence of alcoholism in the Asian popula-
tion [51]. As mentioned above, Asians also have a high incidence of 
the “atypical” active form of ADH1B (i.e., ADH1B*2), which 
means that they rapidly bioactivate ethanol to acetaldehyde but 
slowly detoxify acetaldehyde to acetic acid. Moreover, they also 
have a relatively high prevalence of ADH7 deficiency, which re-
duces the gastric first pass metabolism of ethanol. Collectively 
these data may protect the Asian population against heavy drinking 
and alcoholism [1].  
 ALDH1B1 (mitochondrial) and 1A1 (cytosolic) presented 
higher Km than ALDH2. However, these enzymes may still have 
physiological relevance under certain conditions, especially in 
ALDH2 deficient individuals, and also in the gastrointestinal tract, 
where high levels of acetaldehyde can be generated as a result of 
ethanol metabolism by microorganisms [20]. 
 Finally, it is important to mention that acetaldehyde may be 
present in alcoholic drinks (especially spirits) as a result of the ac-
tion of yeast and bacteria, and also autooxidation [52]. 
ACETATE 
 The oxidation of ethanol by ADH and ALDH leads to the for-
mation of acetic acid. Elevated acetate blood levels have been pro-
posed as an indicator of alcoholism [53]. Most of the acetate pro-
duced leaves the liver, since the need to oxidize the NADH gener-
ated by ADH and ALDH uses 70% to 75% of the oxidative capac-
ity of the organ [54]. The principal isoform of acetyl-CoA syn-
thetase (ACS I) in the liver is a cytosolic enzyme that generates 
acetyl-coenzyme A, which is used for fatty acid and cholesterol 
synthesis. Nevertheless, most acetate enters the systemic circulation 
and is then taken by several tissues such as heart, skeletal muscle, 
and brain, which have a high concentration of mitochondrial acetyl-
CoA synthetase isoform (ACS II) [55]. CoA is then rapidly oxi-
dized to carbon dioxide and water in the Krebs cycle, or is used as a 
substrate for protein acetylation [56]. AMP is also produced from 
acetyl-CoA synthetase activity and is further hydrolyzed by 5’-
nucleotidase to adenosine, which is a powerful physiological vaso-
dilator [57]. Thus, while acetate is generally not considered a toxic 
compound, it can itself have important effects on the body, includ-
ing increased portal blood flow in the liver and central nervous 
system depression, and seems to play a role in hangovers [58, 59]. 
 Notably, acetate is also the major anion product of intestinal 
formation, resulting especially from decarboxylation of pyruvate 
and further acetyl-CoA oxidation by Bacteroids, Clostridium and 
Enterobacterium, and by acetylphosphate oxidation as in Bifidobac-
terium [60]. 
XANTHINE OXIDASE AND ALDEHYDE OXIDASE 
 Besides CY2E1 and ALDH, two metalloflavoproteins, xanthine 
oxidase and aldehyde oxidase, have also proved to oxidize acetal-
dehyde present in tissues [61, 62]. Moreover they are also capable 
of producing O2
.-
 and H2O2 in cells exposed to ethanol. Indeed, 
ethanol stimulates the conversion of xanthine dehydrogenase to O2
.-
-producing oxidase [63]. H2O2 in the presence of transition metals 
(e.g., Fe
2+ 
and Cu
+
) can lead to the formation of HO
.
, radicals that 
are responsible for attacking another molecule of acethaldehyde 
giving rise to methyl carbonyl radical (CH3=O) [64, 65]. 
ETHYL-GLUCURONIDE (EtG) AND ETHYL-SULPHATE 
(EtS) 
 EtG and EtS are direct, non-volatile metabolites of ethanol with 
relevant clinical and forensic applications [66]. EtG and EtS are 
phase II metabolites of ethanol, catalyzed by the enzymes UDP-
glucuronosyltransferase (UGT) superfamily (it utilizes UDP-
glucuronic acid as a cofactor) or sulfotransferase (it utilizes 3’-
phosphoadenosine-5’-phosphosulfate as a cofactor), respectively. 
Less than 2% of the ethanol ingested is metabolized through this 
nonoxidative route [67]. Multiple isoforms of UGT are involved in 
catalyzing the formation of EtG, but only UGT1A1 and UGT2B7 
seem to play a major role [68]. Much less kinetic data is available 
for EtS. 
 Peak EtG serum concentrations typically occur about 4 hours 
after ingestion [69] and after heavy ethanol consumption. EtG and 
EtS may be detectable for up to 8 and 80 hours in blood and urine, 
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respectively [69, 70]. Moreover, within just one hour of consump-
tion of low amounts of ethanol, EtG and EtS are already positive in 
urine and, due to their longer half-life, they are still present in this 
matrix even when ethanol is negative [71]. Therefore, EtG and EtS 
are useful biomarkers for the detection of recent ethanol exposure 
and for abstinence monitoring [7, 72, 73]. 
 However, false positive EtG results may occur, if collected 
urine contains bacteria (e.g., Escherichia coli) and ethanol, which 
might be produced from glucose (e.g., glycosuria in diabetics) and 
yeast by alcoholic fermentation [74]. On the other hand, EtG false 
negative results may be also recorded for urine samples (especially 
if transported and stored improperly without cooling) since this 
metabolite is sensitive to hydrolysis by -glucuronidase present in 
high levels in Escherichia coli, a common cause of urinary tract 
infection) [75-77]. Therefore, refrigeration or frozen storage is rec-
ommended to improve EtG stability in these specimens [75]. Nei-
ther postsampling formation nor degradation has been documented 
in urine samples for EtS [76]. Some studies have reported EtS bio-
degradation only under high bacterial density conditions [77]. Fi-
nally, genetic polymorphisms in UGT and SULT may justify inter- 
and intra-individual differences in the EtG and EtS levels [46]. 
PHOSPHATIDYLETHANOL 
 Other non-oxidative pathway involves the formation of phos-
phatidylethanol (PEth) in the cell membranes. When present, etha-
nol acts as a co-substrate in the transphosphatidylation reaction 
catalyzed by the enzyme phospholipase D (PLD), which inserts 
ethanol in place of choline in phosphatidylcholine [78-80]. PLD has 
a high Km for ethanol, and therefore the reaction would be most 
important predominantly in high circulating ethanol concentrations. 
Two isoforms of phospholipase D have been characterized in hu-
mans. Phospholipase D1 has a perinuclear distribution and requires 
phosphokinase C activation, whereas phospholipase D2 is located in 
the cellular membrane and is constitutively active. However, both 
isoforms of phospholipase D catalyze the formation of PEth in hu-
man erythrocyte membranes [81]. 
 PEth is not a single molecule but a group of abnormal phos-
pholipid homologues. It is formed by a glycerol molecule with two 
fatty acid chains (typically containing 14 to 22 carbon atoms with 0 
to 6 double bonds) in the sn-1 and sn-2 position and with phos-
phoethanol as the head group [82]. At least 48 homologues of PEth 
have been identified in blood [82]. The structure of the most com-
mon PEth homologue is 16:0/18:1 (1-palmitoyl-2-oleosyl-sn-
glycero-3-phosphoethanol). 
 Compared with its formation, the elimination half-life of PEth 
from human blood (mainly in erythrocytes) is slow (approximately 
4 days) [7, 83]. It has been detected in the blood of ethanol abusers 
even up to three weeks after withdrawal [83]. Moreover, PEth con-
centration is highly correlated with the amount of ingested ethanol 
[83]. These facts show that PEth may constitute a promising bio-
marker for the detection of ethanol abuse and for monitoring of 
abstinence [84]. 
 False PEth positive results have been reported, since it can be 
formed in blood samples containing ethanol at -20ºC and at room 
temperature [85, 86]. 
FATTY ACID ETHYL ESTERS (FAEEs) 
 FAEEs are also minor lipophilic nonoxidative products of etha-
nol metabolism [87]. They are formed in almost all tissues by es-
terification of endogenous fatty acids or fatty acyl coenzyme A with 
ethanol, catalyzed by FAEEs synthases. Carboxyl ester lipase and 
glutathione S-transferase have FAEEs synthase activity [87]. 
Triglycerides, lipoproteins and phospholipids (i.e., myristate, palmi-
tate, oleate and stearate) have also been reported to contribute to 
FAEEs formation [68]. 
 Elevated levels of FAEEs are present in blood soon after etha-
nol exposure and may remain detectable for 24 hours to four days 
(especially in heavy drinkers) due to its accumulation in several 
organs and consequent long half-life (approximately 16 hours) [7, 
88, 89]. Moreover, FAEEs analysis of hair and meconium have 
been suggested as suitable biomarkers for documenting long-term 
and prenatal ethanol exposure [7, 90]. Ethyl myristate, ethyl palmi-
tate, ethyl oleate and ethyl stearate have been more frequently ana-
lyzed [91]. 
 Excessive ethanol intake is regarded as one of the major causes 
of acute pancreatitis [1, 92] and FAEEs and fatty acids (and not 
ethanol and acetaldehyde) have been implicated in Ca
2+
-dependent 
necrosis of pancreatic acinar cells [93]. It has been shown that 
FAEEs stimulates the Ca
2+
release from the endoplasmic reticulum, 
possibly by activating IP3 receptors and fatty acids (released from 
the deesterification of FAEEs by intracellular hydrolases) predomi-
nantly inhibit mitochondrial ATP synthesis, which would inhibit 
both Ca
2+
 uptake into the endoplasmic reticulum and Ca
2+
 extrusion 
across the cytoplasm membrane [93, 94]. The consequent global 
elevation of the cytosolic Ca
2+
 concentration triggers necrosis [95]. 
Interestingly, early postmortem studies shown that FAEEs are pre-
sent in the pancreas, at higher concentrations than in any other or-
gan, of patients intoxicated with alcohol at the time of death [96]. 
ETHYL PHOSPHATE (EtP) AND ETHYL NITRITE (EtN)  
 Tomaszewski and Buchowicz [97] first reported the formation 
of EtP in the liver and coined it as another potential biomarker of 
ethanol exposure. Authors hypothesized that EtP may originate 
from ethanolysis of endogenous phosphate esters. Nevertheless, 
very few studies of EtP have been published and it is not yet con-
sidered to be a reliable biomarker [98]. The same is true for EtN, 
which was found in vivo when ethanol and tobacco were consumed 
together [99, 100]. Based on these results, authors suggested that 
EtN is formed as a consequence of ethanol nitrosation by NO, most 
likely by peroxynitrite (ONOO

), a potent oxidizing formed by the 
reaction of NO and O2
.- 
[101]. More recently, Deng et al. [102] also 
proved the formation of EtN in vivo after ethanol administration. 
BACTERIAL METABOLISM OF ETHANOL 
 Microbial ADHs have several physiological (e.g., metabolism 
of endobiotics and xenobiotics) and industrial (e.g., production of 
alcoholic beverages, solvents or vinegar) roles [103]. Under an-
aerobic conditions microorganisms are capable of producing energy 
through fermentation [104]. In the specific case of alcoholic fer-
mentation, acetaldehyde is reduced to ethanol by microbial ADHs 
[105]. Therefore, endogenous ethanol may be produced in the gas-
trointestinal tract and blood, especially in patients with high carbo-
hydrate intake and under cimetidine therapy, which allows bacterial 
overgrowth by increasing gastric pH [106-108]. Besides producing 
endogenous ethanol, microbial ADHs also metabolize ingested 
ethanol to acetaldehyde in the oral cavity, stomach and large intes-
tine. This fact may explain the increased incidence of carcinogene-
sis in the gastrointestinal tract of alcoholics [1, 13, 108] and of gas-
tritis, especially if Helicobacter pylori and Neisseria species are 
colonizing the gastric wall [109]. 
CONCLUDING REMARKS 
 Although moderate ethanol consumption has many health bene-
fits, heavy consumption has toxic effects. Indeed, moderate ethanol 
consumption can increase longevity and reduce the risk of heart 
disease, stroke, certain types of cancer and the risk of neurodegen-
erative diseases such as Alzheimer’s. Conversely, ethanol consump-
tion in excess has been implicated in more than 60 types of dis-
eases, and it is a contributing cause in 200 others [1, 2]. In order to 
understand the toxic effects of ethanol and its mechanisms of pro-
duction, it is fundamental to recognize the importance of metabo-
lism and the multiple routes described above. As a good example, 
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alcoholic liver disease remains a major cause of morbidity and mor-
tality worldwide and its mechanisms of production can be explained 
at least in part by oxidative metabolism [110]. On the other hand, 
minor non-oxidative metabolic pathways of ethanol, such as the 
single-molecules EtG and EtS and the group of molecules FAEE 
and PtE, are direct biomarkers of exposure, and used in various 
clinical and forensic settings, such as workplace and military test-
ing, monitoring consumption if suspected in pregnant women, and 
in ethanol rehabilitation programs. 
 Finally it is important to highlight the effect of age on ethanol 
metabolism since the percentage of individuals aged over 65 is 
steadily increasing. Indeed, it is clear that the elderly exhibit higher 
blood ethanol concentrations, and ethanol metabolism is reduced 
with age due to lower activities of ADH, CYP2E1 and ALDH [111, 
112]. Although not fully clarified, it has been suggested that this 
decrease in metabolic capacity can be explained by liver size reduc-
tion (i.e., reflecting fewer hepatocytes), reduced availability of 
NAD
+
 (i.e., a cofactor for ADH), chronic atrophic gastritis (i.e., 
which influences the activity of ADH7), reduced function of the 
smooth endoplasmic reticulum (and therefore CYP2E1 activity), 
and alterations in mitochondrial transport and number (affecting the 
activity of ALDH) [113-116]. Reduced mitochondrial function may 
lead to increased acetaldehyde levels in the liver, and may also 
explain enhanced fat accumulation in the elderly following ethanol 
ingestion [112]. In addition, blood flow to the liver and the distribu-
tion volume for water soluble substances, such as ethanol, decrease 
with age [111]. 
 All known ethanol metabolites have been reviewed in this 
work, also emphasizing their contributing toxicological effects. 
With the advent of metabolomics, researchers are expecting to 
study the whole “picture” of ethanol metabolism as well as associ-
ated metabolic alterations [49, 117]. Perhaps further metabolites 
formed in a time- and dose-dependent manner and new, different 
pharmacodynamic targets will be discovered, and these may offer 
additional insights into the pathways involved in ethanol toxicity 
and the variability of response. 
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